Susan Galbraith, AstraZeneca EVP of oncology R&D (Rachel Kiki for Endpoints News)

As­traZeneca's Lyn­parza-Imfinzi com­bo clears PhI­II tri­al in ovar­i­an can­cer

As­traZeneca tout­ed pos­i­tive da­ta for its Lyn­parza-Imfinzi block­buster com­bo to­day with a high-lev­el analy­sis from its DUO-O Phase III tri­al, in new­ly di­ag­nosed pa­tients with ad­vanced high-grade ep­ithe­lial ovar­i­an can­cer with­out tu­mor BR­CA mu­ta­tions.

In the in­ter­im analy­sis, As­traZeneca said that in the three-arm tri­al, pa­tients treat­ed with the Lyn­parza-Imfinzi com­bo as well as chemo and be­va­cizum­ab (Avastin) demon­strat­ed a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment in the pri­ma­ry end­point of pro­gres­sion-free sur­vival ver­sus the con­trol group, which was on­ly treat­ed with chemo and be­va­cizum­ab (con­trol arm), but didn’t re­lease spe­cif­ic da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA